Cargando…
Possible roles of sestrin2 in multiple sclerosis and its relationships with clinical outcomes
BACKGROUND: Characterized by demyelination, inflammation and axonal damage, multiple sclerosis (MS) is one of the most common disorders of central nervous system led by the immune system. There is an urgent and obvious need for biomarkers for the diagnosis and follow-up of MS. OBJECTIVE: To investig...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academia Brasileira de Neurologia - ABNEURO
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9173210/ https://www.ncbi.nlm.nih.gov/pubmed/35195231 http://dx.doi.org/10.1590/0004-282X-ANP-2021-0202 |
_version_ | 1784721982464458752 |
---|---|
author | ODABAS, Faruk Omer UCA, Ali Ulvi AKDAG, Turan DEMİRDÖGEN, Filiz ALTAS, Mustafa TOKGOZ, Osman Serhat |
author_facet | ODABAS, Faruk Omer UCA, Ali Ulvi AKDAG, Turan DEMİRDÖGEN, Filiz ALTAS, Mustafa TOKGOZ, Osman Serhat |
author_sort | ODABAS, Faruk Omer |
collection | PubMed |
description | BACKGROUND: Characterized by demyelination, inflammation and axonal damage, multiple sclerosis (MS) is one of the most common disorders of central nervous system led by the immune system. There is an urgent and obvious need for biomarkers for the diagnosis and follow-up of MS. OBJECTIVE: To investigate serum levels of sestrin2 (SESN2), a protein that responds to acute stress, in MS patients. METHODS: A total of 85 participants, 40 patients diagnosed previously with relapsing-remitting MS and 45 healthy controls, were included. Serum SESN2 parameters were investigated in blood samples drawn from each participant in the patient and control groups. RESULTS: SESN2 levels were significantly lower in MS patients than in controls (z: -3.06; p=0.002). In the ROC analysis of SESN2, the predictive level for MS was 2.36 ng/mL [sensitivity, 72.50%; specificity, 55.56%; p=0.002; area under the curve (AUC)=0.693]. For the cut-off value in both groups, SESN2 was an independent predictor for MS [Exp (B)=3.977, 95% confidence interval (95%CI) 1.507-10.494 and p=0.013]. CONCLUSIONS: The decreased expression of SESN2 may play a role in MS pathogenesis, and SESN2 could be used as a biomarker for MS and as immunotherapeutic agent to treat MS. |
format | Online Article Text |
id | pubmed-9173210 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Academia Brasileira de Neurologia - ABNEURO |
record_format | MEDLINE/PubMed |
spelling | pubmed-91732102022-12-08 Possible roles of sestrin2 in multiple sclerosis and its relationships with clinical outcomes ODABAS, Faruk Omer UCA, Ali Ulvi AKDAG, Turan DEMİRDÖGEN, Filiz ALTAS, Mustafa TOKGOZ, Osman Serhat Arq Neuropsiquiatr Articles BACKGROUND: Characterized by demyelination, inflammation and axonal damage, multiple sclerosis (MS) is one of the most common disorders of central nervous system led by the immune system. There is an urgent and obvious need for biomarkers for the diagnosis and follow-up of MS. OBJECTIVE: To investigate serum levels of sestrin2 (SESN2), a protein that responds to acute stress, in MS patients. METHODS: A total of 85 participants, 40 patients diagnosed previously with relapsing-remitting MS and 45 healthy controls, were included. Serum SESN2 parameters were investigated in blood samples drawn from each participant in the patient and control groups. RESULTS: SESN2 levels were significantly lower in MS patients than in controls (z: -3.06; p=0.002). In the ROC analysis of SESN2, the predictive level for MS was 2.36 ng/mL [sensitivity, 72.50%; specificity, 55.56%; p=0.002; area under the curve (AUC)=0.693]. For the cut-off value in both groups, SESN2 was an independent predictor for MS [Exp (B)=3.977, 95% confidence interval (95%CI) 1.507-10.494 and p=0.013]. CONCLUSIONS: The decreased expression of SESN2 may play a role in MS pathogenesis, and SESN2 could be used as a biomarker for MS and as immunotherapeutic agent to treat MS. Academia Brasileira de Neurologia - ABNEURO 2022-02-21 /pmc/articles/PMC9173210/ /pubmed/35195231 http://dx.doi.org/10.1590/0004-282X-ANP-2021-0202 Text en https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License |
spellingShingle | Articles ODABAS, Faruk Omer UCA, Ali Ulvi AKDAG, Turan DEMİRDÖGEN, Filiz ALTAS, Mustafa TOKGOZ, Osman Serhat Possible roles of sestrin2 in multiple sclerosis and its relationships with clinical outcomes |
title | Possible roles of sestrin2 in multiple sclerosis and its relationships with clinical outcomes |
title_full | Possible roles of sestrin2 in multiple sclerosis and its relationships with clinical outcomes |
title_fullStr | Possible roles of sestrin2 in multiple sclerosis and its relationships with clinical outcomes |
title_full_unstemmed | Possible roles of sestrin2 in multiple sclerosis and its relationships with clinical outcomes |
title_short | Possible roles of sestrin2 in multiple sclerosis and its relationships with clinical outcomes |
title_sort | possible roles of sestrin2 in multiple sclerosis and its relationships with clinical outcomes |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9173210/ https://www.ncbi.nlm.nih.gov/pubmed/35195231 http://dx.doi.org/10.1590/0004-282X-ANP-2021-0202 |
work_keys_str_mv | AT odabasfarukomer possiblerolesofsestrin2inmultiplesclerosisanditsrelationshipswithclinicaloutcomes AT ucaaliulvi possiblerolesofsestrin2inmultiplesclerosisanditsrelationshipswithclinicaloutcomes AT akdagturan possiblerolesofsestrin2inmultiplesclerosisanditsrelationshipswithclinicaloutcomes AT demirdogenfiliz possiblerolesofsestrin2inmultiplesclerosisanditsrelationshipswithclinicaloutcomes AT altasmustafa possiblerolesofsestrin2inmultiplesclerosisanditsrelationshipswithclinicaloutcomes AT tokgozosmanserhat possiblerolesofsestrin2inmultiplesclerosisanditsrelationshipswithclinicaloutcomes |